伊贝沙坦与缬沙坦治疗高血压病的疗效和安全性的临床研究

目的对比观察伊贝沙坦和缬沙坦治疗轻、中度高血压病病人的临床疗效与安全性.方法采用随机、开放、平行、单盲对照方法,伊贝沙坦(n=68)组每目150 mg或加用双氢克尿噻12.5 mg,缬沙坦(n=66)组每日80 mg或加用双氢克尿噻12.5mg,观察治疗6周、8周和12周后的有效率和副反应发生率.结果两组治疗第2周开始收缩压(SBP)、舒张压(DBP)较治疗前均明显降低(P<0.01);在整个治疗期间血压持续平稳下降,而服药8周伊贝沙坦组降压效果稍优于缬沙坦组,总有效率伊贝沙坦组为69.1%和缬沙坦组为63.6%;治疗12周后加用双氢克尿噻总有效率为89.5%和84.8%;动态血压监测(ABPM)显示伊贝沙坦的谷峰比值和降低清晨血压骤升与缬沙坦相似(P>0.05).副反应两组均很轻微.结论 伊贝沙坦和缬沙坦均是有效、安全的血管紧张素Ⅱ受体拮抗剂的长效降压药,而伊贝沙坦各方面表现与缬沙坦相似.

Clinical Study of Irbesartan and Valsartan for Essential Hypertension

Objective To evaluate of clinic efficacy and safety of Irbesartan and Valsartan for essential hypertension.Methods One hundred and thirty-four patients were divided into two group randomly: Irbesartan group (n=68),treated with Irbesartan 150 mg daily,or combined with Hydrochlorothiazide 12.5 mg daily;Valsrtan group (n=66),treated with Valsartan 80mg daily,or combined with hydrochlorothiazide 12.5 mg daily.The clinic efficacy and the side effect were evaluated following 6 and 8 and 12 week.Results The average systolic blood pressure (SBP), average diastolic blood pressure (DBP) decreased significantly in both groups following 2 week therapy (P<0.01).The blood pressure decreased continuously and smoothly during the entire therapy.The total efficacy rate was 69.1% for Irbesartan group and 63.6% for Valsartan group following the 8 week therapy (P>0.05). The total efficacy rate is 85% for Irbesrtan with hydrochlorothiazide and 84.8% for Valsartan with hydrochlorothiazide after 12 weeks' treatment (P>0.05). The side effective was rare during therapy in both groups.Conclusion Irbesartan and Valsartan are the effective, safe anti-hypertension agents.